Colivelin

SKU: orb1219826

Description

Colivelin is a neuroprotective peptide and activator of STAT3. Colivelin is a hybrid peptide synthesized to enhance the neuroprotective effects of humanin (HN).Colivelin is a hybrid peptide composed of ADNF and AGA-(C8R)HNG17, a potent Humanin (HN) derivative. Humanin (HN) and its derivatives, such as Colivelin (CLN), suppress neuronal death induced by insults related to Alzheimer's disease (AD) by activating STAT3. Colivelin completely suppresses death induced by overexpressed FAD-causative genes and A 1-43 at a concentration of 100 fM, whereas AGA-(C8R)HNG17 does so at a concentration of 10 pM.Humanin (HN) and its derivatives, such as Colivelin (CLN) also ameliorate functional memory impairment of mice induced by anticholinergic drugs or soluble toxic amyloid-β (Aβ) Intracerebroventricular administration of Colivelin not only completely suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, but also it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42.

Key Properties

• CAS Number: 867021-83-8
• MW: 2645.1
• Purity: >98% (HPLC)
• Formula: C₁₁₉H₂₀₆N₃₂O₃₅
• Target: STAT
• Solubility: In Vitro: DMSO : 100 mg/mL (37.81 mM)

Bioactivity

• In Vivo:
  Colivelin (intracerebroventricular administration; 10 pmol/3 μl; 3 weeks) suppresses impairment in spatial working memory induced by repetitive intracerebroventricular injection of Aβ25-35 or Aβ1-42, in addition, it antagonizes neuronal loss in the CA1 region of hippocampus induced by hippocampal injection of Aβ1-42.Colivelin (intraperitoneal administration; 1.4, 7, or 35 nM/0.21 mL; on the Y-maze testday) suppresses memory impairment caused by3-quinuclidinyl benzilateand restricts functional memory deficit. Colivelin (intraperitoneal injection; 1 mg/kg; 14 days) results in improved motor and cognitive function with time by performance of mNSS, rotarod, and corner turning test. It also reduces lesion volume and improves neurological deficits after MCAO. Animal model: CD-1 mice. Dosage: 10 pmol/3 μl. Administration: Intracerebroventricular administration. Result: Completely suppressed Aβ 25-35-mediated impairment in spatial working memory and increased the number of immunoreactive neurons. Animal model: C57 mice. Dosage: 1.4, 7, or 35 nM/0.21mL. Administration: Intraperitoneal administration. Result: Protected against cholinotoxin-induced amnesia in mice. Animal model: Male C57BL/6 mice. Dosage: 1 mg/kg. Administration: Intraperitoneal administration. Result: Protected against ischemic brain injury, and improves neurological outcomes.
• In Vitro:
  Colivelin completely suppresses death induced by overexpressed FAD-causative genes and Aβ1-43 at a concentration of 100 fm, and keep its neuroprotective action at or above the levels of 1 nm. Colivelin-induced neuroprotection occurs via two neuroprotective pathways: one mediated by Ca2+/calmodulin-dependent protein kinase IV, triggered by ADNF, and one mediated by signal transducer and activator of transcription 3, triggered by HN. Colivelin reverses caspase3, Bax and Bcl-2 expressions in HT22 cells medaited by rmMFG-E8 in the co-cultured cells under OGD condition. Colivelin (50 μg/mL, 4 hours) significantly increases the p-STAT3 protein levels in BV-2 cells. Western blot analysis. Cell line: BV-2 cells. Concentration: 50 μg/mL. Incubation time: 4 hours. Result: Increased p-STAT3 levels. Cell Viability Assay Cell line: KYSE70 and TE8 cells. Concentration: 0.5 μM. Incubation time: 1 hour (followed by CYT-Rx20 treatment). Result: Sgnificantly suppressed the viability in KYSE70 and TE8 cells.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

STAT